Erytech Pharma (NASDAQ:ERYP)‘s stock had its “buy” rating restated by equities research analysts at Cowen in a note issued to investors on Sunday, AnalystRatings.com reports.
ERYP has been the subject of a number of other reports. JMP Securities reaffirmed a “market outperform” rating and set a $13.00 price target on shares of Erytech Pharma in a research report on Thursday, September 5th. Zacks Investment Research downgraded Erytech Pharma from a “hold” rating to a “sell” rating in a research report on Thursday, September 19th. Finally, ValuEngine raised Erytech Pharma from a “hold” rating to a “buy” rating in a research report on Thursday, August 15th.
Shares of Erytech Pharma stock traded up $0.11 on Friday, hitting $4.91. 3,500 shares of the company’s stock traded hands, compared to its average volume of 842. Erytech Pharma has a one year low of $3.95 and a one year high of $10.65. The company has a debt-to-equity ratio of 0.08, a current ratio of 5.91 and a quick ratio of 5.90. The company has a fifty day moving average of $4.49 and a two-hundred day moving average of $5.99. The company has a market capitalization of $86.11 million, a price-to-earnings ratio of 2.01 and a beta of 1.48.
Several hedge funds and other institutional investors have recently made changes to their positions in the company. Sphera Funds Management LTD. purchased a new position in shares of Erytech Pharma in the third quarter valued at $1,046,000. Delek Group Ltd. bought a new stake in Erytech Pharma during the fourth quarter valued at $1,539,000. Jane Street Group LLC bought a new stake in Erytech Pharma during the fourth quarter valued at $607,000. Millennium Management LLC bought a new stake in Erytech Pharma during the fourth quarter valued at $959,000. Finally, BVF Inc. IL bought a new stake in Erytech Pharma during the fourth quarter valued at $13,763,000. Institutional investors own 8.13% of the company’s stock.
Erytech Pharma Company Profile
ERYTECH Pharma SA, a biopharmaceutical company, develops therapies for severe forms of cancer and orphan diseases. It is developing a pipeline of product candidates targeting solid and liquid tumors for patients with high unmet medical needs. The company's lead product candidate is eryaspase, which is used for the treatment of severe solid tumors, including pancreatic cancer and in acute lymphoblastic leukemia.
Read More: What is the Rule of 72?
Receive News & Ratings for Erytech Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Erytech Pharma and related companies with MarketBeat.com's FREE daily email newsletter.